Corbus Pharmaceuticals Holdings Inc. closed 89.03% below its 52-week high of $61.90, which the company reached on July 31st.
Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report)‘s stock had its “outperform” rating reaffirmed by research analysts at ...
Zacks Investment Research on MSN1d
Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's What You Should KnowCorbus Pharmaceuticals (CRBP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...
The stock's fall snapped a two-day winning streak.
Oppenheimer analyst Jeff Jones reiterated a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today and set a price target of ...
RBC Capital analyst Brian Abrahams maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) yesterday and set a price target ...
Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) had its price target lowered by Jefferies Financial Group from $70.00 to $53.00 in a research report report published on Tuesday,Benzinga reports.
CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western study Fast Track Designation granted by ...
Participants in HNSCC, cervical, and mUC tumors are being randomized to the 2.7 mg/kg and 3.6 mg/kg cohorts. Price Action: CRBP stock is down 8.23% at $8.70 at the last check on Friday.
Corbus Pharmaceuticals Holdings Inc. (CRBP) on Tuesday reported a loss of $9.5 million in its fourth quarter. The Norwood, Massachusetts-based company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback